Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Your access key has expired

AccuraGen, a US-China Cancer Diagnostics Company, Raises $40 Million

publication date: Jun 1, 2016
AccuraGen Holdings, a US-China cancer diagnostics company, has closed a $40 million Series B financing. AccuraGen develops blood tests that sequence cell free DNA (cfDNA) to provide sensitive and accurate cancer diagnostics. Its current product, which is undergoing clinical tests in China, is a 61-gene assay. Participants in the Series B include Junson Capital, Decheng Capital, Temasek investments, DT Capital, Stanford‐StartX Fund, and Nan Fung Capital, along with existing Series A investors. More details....

Share this with colleagues:  



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here